The administration of<unk>  in large amounts by ingestion or intramuscular administration during the onset of pregnancy can cause fetal abnormalities—when administered to pregnant rats, mice and rabbits,<unk>  caused abnormalities such as hypogonadism with doses significantly above that of the human therapeutic range. In humans, a significant dose has not yet been established in studies, and by default, the Food and Drug Administration (FDA) has introduced contraindication guidelines in regard to<unk> . Similarly the use in those at risk from or showing previous signs of hypersensitivity is also contraindicated.<unk>  is contraindicated for intravenous (IV) injection, as it has shown to cause hemolysis. Other contraindications include the administration of<unk>  alongside depressants and other compounds which affect the central nervous system; if absolutely necessary, it should only be administered concomitantly in small doses. If administered in small doses with other substances, such as mentioned, then patients should refrain from using dangerous machinery, motor vehicles or any other practice requiring absolute concentration, in accordance with safety law. Studies have also been conducted which show that long-term prescription of<unk>  can lead to tardive dyskinesia after years of use, but effects related to dyskinesia have also anecdotally been reported after periods of 7.5 months, such as continual head rolling, lip licking and other forms of athetoid movement. In certain cases, elderly patients' previous interactions with phenothiazine derivatives or pre-existing neuroleptic treatment may have had some contribution towards dyskinesia at the administration of<unk>  due to hypersensitivity caused due to the prolonged treatment, and therefore some contraindication is given to the short-term administration of<unk>  to those with previous phenothiazine use.
Hydroxyzine
Naltrexone
Nabilone
Chloracyzine
Phenelzine
Nortriptyline
Ketanserin
Promethazine